P/E của cổ phiếu ACAD là bao nhiêu?

Acadia Pharmaceuticals Inc (ACAD) hiện giao dịch ở mức P/E 11.67 lần.

ROE của cổ phiếu ACAD là bao nhiêu?

Acadia Pharmaceuticals Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 30.10%.

Tỷ suất cổ tức của ACAD là bao nhiêu?

Acadia Pharmaceuticals Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của ACAD là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của ACAD ở mức 62/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu ACAD không?

Điểm AI Timing của ACAD là 91/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu ACAD thuộc ngành nào?

Acadia Pharmaceuticals Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu ACAD (NASDAQ) | ACADIA PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

ACAD AI Analysis Summary

Our AI summary for ACAD: Acadia Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 11.67, ROE of 30.10%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ACAD

Acadia Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 27.15

1.54 (6.01%) Day Change

Watchlist Portfolio Compare Chart

11.67

P/E

0.01

D/E

30.1%

ROE

23.4%

ROA

0.00%

Div Yield

ACADIA PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 27.15 Price 1.54 (6.01%) Day Change	NEWS SCORE: 99

ACAD Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 62) và Thời điểm mua ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: [-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...

Yếu tố Chất lượng

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	207
Magic Formula Rank by ROE	207
Magic Formula Rank by ROIC	375
Price	27.15
PBV / Sector	3.51 / 44,022.72
Earning Per Share	2.33

PE / Sector	11.67 / 19.17 GOOD
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	36.27 M GREAT
Average 1W Daily Value	43.08 M GREAT

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	34.30 / 98.24 GREAT
NPM Average (%) / Sector	8.85 / -1,697.63
NPM Change Average (%) / Sector	-102.93 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	23.40 / 185,260.96 GOOD
ROA Average (%) / Sector	4.51 / 36,684.70
ROA Change Average (%) / Sector	-96.50 / 422,221.66
ROE (%) / Sector	30.10 / 243,762.23 GREAT
ROE Average (%) / Sector	4.94 / 48,758.47
ROE Change Average (%) / Sector	-98.46 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Chi tiết đăng ký

Analyze Date	2026-08-05 07:59:46
Symbol	ACAD
Name	ACADIA PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	171.24 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4,385.35 / 9,586.08

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12830 El Camino Real, San Diego, CA, United States, 92130

Phone: 858 558 2871

Website: https://www.acadia.com

Employees: 796

Sector: Healthcare >> Biotechnology

Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.